Curated News
By: NewsRamp Editorial Staff
November 12, 2025
Co-Diagnostics Expands to Saudi Arabia with New Joint Venture
TLDR
- Co-Diagnostics gains strategic advantage by establishing CoMira Diagnostics joint venture in Saudi Arabia, expanding its patented PCR platform across Middle East and North Africa markets.
- Co-Diagnostics forms CoMira Diagnostics through a definitive joint venture agreement with Arabian Eagle to localize manufacturing and distribution of its molecular diagnostic tests in Saudi Arabia.
- Co-Diagnostics' expansion into Middle Eastern markets through CoMira Diagnostics will improve global healthcare access by providing advanced diagnostic tools to more patients worldwide.
- A Utah-born diagnostics company recognized by Governor Cox is now competing globally through a Saudi joint venture that localizes PCR technology across the Middle East.
Impact - Why it Matters
This expansion matters because it represents a significant advancement in global healthcare accessibility, particularly for the Middle East and North Africa region. By localizing advanced PCR diagnostic technology through the CoMira Diagnostics joint venture, patients in these regions will gain improved access to cutting-edge molecular testing capabilities. This development accelerates the globalization of diagnostic technologies that were previously concentrated in Western markets, potentially leading to earlier disease detection, better outbreak management, and more personalized medical treatments. For the global healthcare community, it demonstrates how regional partnerships can effectively transfer sophisticated medical technology, potentially creating a blueprint for future international healthcare collaborations that bridge technological gaps between developed and developing markets.
Summary
Utah Governor Spencer Cox and BioUtah President Kelvyn Cullimore have publicly recognized Co-Diagnostics, Inc. for its significant international expansion following the company's recent announcement of a groundbreaking joint venture in Saudi Arabia. The Salt Lake City-based molecular diagnostics company, trading on Nasdaq as CODX, has signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics, a new entity that will localize Co-Dx PCR platform technology across the Middle East and North Africa region. This strategic move represents a major step in global healthcare accessibility and demonstrates Utah's growing influence in the life sciences sector.
The formation of CoMira Diagnostics marks a pivotal moment for Co-Diagnostics' international presence, with Governor Cox emphasizing how the "Utah-born company competing on the world stage" reflects the strength of the state's life sciences industry and entrepreneurial spirit. Cullimore further highlighted that this expansion "confirms Co-Diagnostics' expanding leadership and presence on the worldwide stage," noting the company's Elite membership status within BioUtah. The joint venture specifically focuses on localizing the Co-Dx PCR platform, which includes both at-home and point-of-care diagnostic solutions currently undergoing regulatory review, though not yet available for commercial sale.
Co-Diagnostics specializes in developing advanced molecular diagnostic tests using its patented technology platform designed to detect and analyze nucleic acid molecules, including DNA and RNA. Beyond infectious disease applications, the company's proprietary technology also identifies genetic markers for various other medical applications. BioUtah, as Utah's leading life sciences trade association, represents the state's diverse healthcare innovation ecosystem spanning medical devices, biotechnology, pharmaceuticals, and diagnostics. This recognition ceremony underscores how Utah-based companies are increasingly making global impacts in healthcare technology and diagnostics innovation.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Co-Diagnostics Expands to Saudi Arabia with New Joint Venture
